The biosimilars market has the potential to disrupt the healthcare industry by exponentially increasing market access and providing the highest quality at the lowest cost to an untreated patient population which cannot afford $100,000 therapies. According to Frost & Sullivan, the global biosimilar market is expected to grow from $1.7 billion in 2014 to $30 billion by 2020, representing a CAGR of 62.1 percent. Europe is the largest contributor of biosimilar revenues worldwide. Strong government support and established incentive mechanisms have boosted rapid growth. While the U.S. is the largest biologics market globally, it currently accounts for only a small part of the global biosimilars market. The emergence of a supportive regulatory approval pathway for biosimilars and patent expiries on major biological products are expected to change this situation.

During this discussion, we will illuminate key trends, challenges and success factors in global biosimilars industry. We will explore different strategies formulated by biologics companies to develop or expand, independently or through partnerships, their position in the biosimilars market, and at the same time defend its product portfolio against biosimilar competition. The contents of your collective conversation will feed the article Frost & Sullivan is writing titled "Commercialization Strategies in Global Biosimilars Industry."  Based on past experiences, we expect you to leave with a ton of great takeaways and new connections with industry peers. (See below for feedback from past research think tanks).

PLANNED TOPICS OF DISCUSSION:

• What is the expected impact of emerging markets?
• Which unique business capabilities are required to ensure success in biosimilars market?
• What are changing regulations that will impact both biosimilars and biobetters?
• What cost savings optimization strategies are expected to be implemented for biosimilars - either for Non-original biologics or biobetters?
• How will market respond to increasing competition?
• What social and market requirement will favor acceleration of biosimilars’ adoption?